I dunno tJ--Im still looking at the depth--sell 4551@285---buy 400@275
Im not surprised they got approval--its a combination of 2 of the most common ingredients around--just doesnt seem like the sort of thing to take the medical world by storm--(no reason not to use it though--Im sure it will keep selling,but I think you will need some sort of breakthrough (from the research)to really make traction.
Right now there is heaps of positivity on the NZX so if it doesnt happen today ,or soon,might be alot of waiting.
Simply stunning, one would think this sort of break through would certainly push it over $3!
Cautiously optimistic. An initial step in what will be a long process for FDA approval in clinical application.
Here's the link to one of their trials from the US if your clinically inclined. https://clinicaltrials.gov/ct2/show/NCT02689063
It is similar to the trial which will be piloted in Christchurch
Speaking to my colleagues in the pain management field, there are still a myriad of issues concerning IV administration of NSAIDs
The big question is just how much dosh they are churning through with the research,and whether they are coming up with anything--I wonder if they would not be better off just promoting their established product(but whats the difference between just taking 1/2 tab of ibuprofen and 1/2 of paracetimal (i did the spell check on the misspelling of para and it told me ''malpractice'' --you gotta laugh sometimes)
Theres probably a big difference but Ive often wondered
I was asked by my chemist what I thought of AFT.
Told him I would find out what I could.
So 96,834,838 shares on issue,giving at $2.95 a market capitalisation of $285,662,772.
Half year to 30th September 2015;
Revenue $29,543,000
Nett loss $6,367,000.
Next report due 25th May .
Conculsion.The market is factoring in a lot of "blue skies".Be careful.
Bookmarks